#ferring pharmaceutical

[cdifffoundation]

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, Announced Final Results of An Analysis From Five Prospective Trials Of Its Investigational Microbiota-Based Live Biotherapeutic RBX2660

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, Announced Final Results of An Analysis From Five Prospective Trials Of Its Investigational Microbiota-Based Live Biotherapeutic RBX2660

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection (rCDI). The abstract, presented at IDWeek 2021, represents the first time these data are showcased together, and is one of only four abstracts…

View On WordPress

[cdifffoundation]

CDI and Recurrence; Microbiome - Based Therapy Publication

CDI and Recurrence; Microbiome – Based Therapy Publication

                                To read the article in its entirety, please download the .pdf format below 2021-MicrobiomeBasedTherapyCDI    

View On WordPress

[cdifffoundation]

Rebiotix and Ferring Pharmaceuticals Announced Positive Preliminary Findings From Their Ongoing Pivotal Phase 3 Trial Of the Investigational Microbiome-based Treatment RBX2660

Rebiotix and Ferring Pharmaceuticals Announced Positive Preliminary Findings From Their Ongoing Pivotal Phase 3 Trial Of the Investigational Microbiome-based Treatment RBX2660

This is a promising approach to managing CDI. Completion of a Phase 3 study, with positive results, is exciting and holds much promise for patients suffering with recurrent C. diff. infections. We look forward to the final results and are truly grateful.

  Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660

View On WordPress

[cdifffoundation]

Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial RBX2660

Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial RBX2660

Rebiotix, a Ferring Company, completes enrollment for first-ever, pivotal Phase 3 Clinical Trial of Microbiota -based RBX2660

Enrollment completion for the first Phase 3 clinical trial in microbiome industry

 The largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the potential benefit of RBX2660 in reducing rates of recurrent Clostridioides difficile…

View On WordPress

[cdifffoundation]

Ferring Pharmaceuticals Acquires Rebiotix, Inc.

Ferring Pharmaceuticals Acquires Rebiotix, Inc.

Ferring acquires innovative biotechnology company and microbiome pioneer Rebiotix Inc.

Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product

CDI is one of the most common healthcare-associated infections in the US, affecting more…

View On WordPress